Greenway Schond L.
Greenway Schond L.'s purchase track record
Greenway Schond L. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/10/2021 | AVTX | $4K | -63.2% | -75.1% | -17.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Avalo Therapeutics Reports Phase 2 Progress on IL-1β Program. Avalo Therapeutics disclosed Phase 2 validation for its IL-1β franchise, a development that could expand the company's pipeline in inflammatory disease treatments. The biotech firm also announced inducement stock grants to new hires under Nasdaq listing rules and scheduled participation in investor conferences, routine corporate activities that signal active business expansion. The stock trades within its 52-week range, with the analyst consensus target notably above current levels.
Transaction History
| DFTX | ▼ Sell | Tax Withholding | 5,560 | $54K | 3/25/2024 | View on chart |
| DFTX | ▼ Sell | Open Market | 5,652 | $21K | 12/26/2023 | View on chart |
| DFTX | ▼ Sell | Open Market | 1,908 | $7K | 9/25/2023 | View on chart |
| DFTX | ▼ Sell | Open Market | 3,854 | $14K | 9/25/2023 | View on chart |
| DFTX | ▼ Sell | Open Market | 20,000 | $76K | 8/25/2023 | View on chart |
| DFTX | ▼ Sell | Open Market | 7,694 | $25K | 6/27/2023 | View on chart |
| DFTX | ▼ Sell | Open Market | 3,941 | $13K | 6/27/2023 | View on chart |
| DFTX | ▲ Buy | Grant | 175,000 | $0 | 3/14/2023 | View on chart |
| DFTX | ▲ Buy | Grant | 1,270,000 | $0 | 5/23/2022 | View on chart |
| AVTX | ▲ Buy | Open Market | 2,231 | $4K | 12/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
JP Morgan Launches Coverage of DFTX with Overweight Rating
JP Morgan has started covering Definium Therapeutics and gave it an overweight rating. The bank set a price target of $84, well above the stock’s 52‑week high of $49.70. This new coverage signals that JPMorgan sees potential upside in the company. The rating and target may affect how investors view the stock.
JP Morgan Launches Coverage of DFTX with Overweight Rating. JP Morgan has started covering Definium Therapeutics and gave it an overweight rating. The bank set a price target of $84, well above the stock’s 52‑week high of $49.70. This new coverage signals that JPMorgan sees potential upside in the company. The rating and target may affect how investors view the stock.